CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and core operating income rising 29% in constant currency. For the full year, the company achieved a ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

The company says it conducted a thorough evaluation of internal and external candidates, but decided that Vasant Narasimhan, known as Vas, was the best candidate to take the company forward.

In a significant development, Novartis' CEO Vas Narasimhan has sounded the alarm over the United States' decision to exit the World Health Organization, raising concerns about the potential ...

CEO Vas Narasimhan said the results marked a positive early signal since implementing a strategic overhaul in 2023 to ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, ...